Clinical trials in Zabrze – page 35

1 174 clinical trials in Zabrze, Poland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Zabrze at a glance

1 174

clinical trials

Research sites3

Quick filters

1 174 trials in Zabrze

Open in trial search

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Rezpegaldesleukin
Sponsor:Nektar Therapeutics

Contact Research Centre

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Cenerimod
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:EXPD-101
Sponsor:Expedition Therapeutics Inc.

Contact Research Centre

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Olatorepatide
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Atumelnant
Sponsor:Crinetics Pharmaceuticals Inc.

Contact Research Centre

Colitis ulcerative

Not yet recruiting

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational

Phase 2b Study of ATH-063 in Adults with Biologic‑Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis

Investigational

Poland

Participants:18–64 years
Substances:ATH-063 hydrochloride
Sponsor:Athos Therapeutics Inc.

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Zabrze

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking trials focusing on heart failure treatment and prevention, including studies of novel drug combinations like baxdrostat/dapagliflozin and sacubitril/valsartan. Research encompasses various cardiac conditions, from post-myocardial infarction care to atrial fibrillation management.

Heart Failure Prevention
Cardiomyopathy Treatment
Post-Transplant Care

Multiple studies are examining innovative approaches to cardiac health management and prevention strategies.

02 Neurological Disorders

Advanced clinical research in multiple sclerosis treatments, testing new therapies like frexalimab and ublituximab. Studies also include innovative approaches to treating Alzheimer's disease and chronic inflammatory demyelinating polyneuropathy.

Multiple Sclerosis Management
Dementia Treatment
Neuropathy Research

Trials focus on improving patient outcomes and developing more effective treatment protocols.

03 Metabolic Conditions

Comprehensive studies addressing obesity management and diabetes control, particularly in adolescent populations. Research includes evaluation of new treatments like tirzepatide and innovative insulin therapies.

Weight Management
Type 2 Diabetes
Growth Disorders

Research aims to develop more effective treatments for metabolic disorders across different age groups.

Back to Poland All countries